411 filings
6-K
REPCF
Replicel Life Sciences Inc.
20 Mar 24
RepliCel announces a Letter of Intent for Asset Purchase Agreement
4:38pm
6-K
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
6-K
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
6-K
REPCF
Replicel Life Sciences Inc.
19 Oct 23
Current report (foreign)
1:45pm
6-K
REPCF
Replicel Life Sciences Inc.
4 Oct 23
RepliCel Provides Default Status Update and Announces Shareholder Approval of Equity Incentive Plan
2:23pm
6-K
v829fja5z
13 Sep 23
RepliCel Announces DermaPreciseā¢ Development Milestone, Updates Arbitration Proceedings
5:32pm
6-K
lqt4mw
7 Sep 23
Current report (foreign)
12:26pm
6-K
w1cxbfmx
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
6-K
iy8d8i67t47am6
29 Aug 23
RepliCel announces the passing of long time Chief Financial Officer Simon Ma; David Kwok is appointed Chief Financial Officer
1:14pm
6-K
xc7xsbjt2t0 u0v9
17 Aug 23
Annual General and Special Meeting
11:22am
6-K
kv3eokfca 4fy
9 Aug 23
Statement of Executive Compensation
7:41pm
6-K
oy1 bs8b2h3
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
7370ph5x6hq6teyf94oq
18 May 23
RepliCel Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options
1:58pm
SC 13D/A
7gq0zib
20 Apr 23
REPLICEL LIFE SCIENCES / Schutte Andrew ownership change
1:03pm
6-K
lfd0y6dj73hkc
21 Mar 23
RepliCel Announces Shareholder Approval of 10% Rolling Stock Option Plan
4:56pm
D
dospafm9q2r5d8r39
16 Mar 23
$740.78 k in equity / options / securities to be acquired, sold $740.78 k, 5 investors
2:39pm
6-K
ldoe1d2
23 Feb 23
RepliCel Announces Settlement of Payment of Dividend on Preferred Shares
11:54am
6-K
8sus2rju
23 Feb 23
RepliCel Life Sciences Announces Intention to Pay Dividend on Preferred Shares
11:42am
D
yhzbi6
7 Feb 23
$9.20 k in equity, sold $9.20 k, 1 investor
5:48pm